Prospective, randomised, open label, multicentre Phase II clinical trial to investigate the efficacy and safety of the treatment of large defects (4-10 cm2) with 3 different doses of the autologous chondrocyte transplantation product co.don chondrosphere (ACT3D-CS) in subjects with cartilage defects of the knee

Trial Profile

Prospective, randomised, open label, multicentre Phase II clinical trial to investigate the efficacy and safety of the treatment of large defects (4-10 cm2) with 3 different doses of the autologous chondrocyte transplantation product co.don chondrosphere (ACT3D-CS) in subjects with cartilage defects of the knee

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2018

At a glance

  • Drugs Autologous cultured chondrocytes (Primary)
  • Indications Knee injuries
  • Focus Therapeutic Use
  • Sponsors co.don AG
  • Most Recent Events

    • 16 Apr 2018 New trial record
    • 05 Apr 2018 According to the co.don AG media release, interim results collected annually over the four-year follow-up period and five-year follow-up examination was carried out for the last patient in early 2018, which was followed by final statistical analysis and evaluation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top